The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%, till 2030 :>

Roots Analysis has done a detailed study on Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 450+ page report, which features 120+ figures and 140+ tables, please visit this link 
Key Market Insights 
  • Over 80 companies are offering antibody discovery services; of these, more than 75 players claim to offer services related to hit generation.
  • Nearly 180 innovative technology platforms have been developed by numerous firms for the purpose of antibody discovery.
  • Majority of stakeholders in the competitive market landscape are small / mid-sized firms, catering to the needs of a diverse clientele.
  • In order to get an edge over their competitors in the industry, companies have established their presence in different regions across the globe.
  • The rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on antibody discovery for diverse range of indications.
  • Efforts of the players in the field of antibody discovery have garnered significant interest of several venture capital investors.
  • The antibody discovery services market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various steps involved in antibody discovery, antibody discovery method, nature of antibody generated and geographies.
  • The market for antibody discovery platforms is currently being driven by the revenues from the licensing deals; it is anticipated to reach USD 5.9 billion by 2030.


For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html
                                                                                                               

Table of Contents

 
1.         PREFACE
1.1.        Scope of the Report
1.2.        Research Methodology
1.3.        Chapter Outlines
 
2.         EXECUTIVE SUMMARY
 
3.         INTRODUCTION
3.1.       Chapter Overview
3.2.       Structure of Antibodies
3.3.       History of Development
3.4.       Antibody Isotypes
3.5.       Mechanism of Action of Antibodies 
3.6.       Classification of Antibodies
3.6.1.    Monoclonal Antibodies
3.6.2.    Polyclonal Antibodies
3.6.3.    Bispecific Antibodies
3.7.       Applications of Antibodies
 
 
 
Press Release: Variation 2 (Format 3)
 
4.         ANTIBODY DISCOVERY PROCESS AND METHODS
4.1.       Chapter Overview
4.2.       Antibody Discovery Process
4.2.1.    Target Selection and Validation
4.2.2.    Hit Generation
4.2.3.    Lead Selection
4.2.4.    Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5.    Lead Characterization
4.2.6.    Candidate Selection
 
4.3.       Antibody Discovery Methods
4.3.1.    Hybridoma Method
4.3.2.    In vitro Display Method
4.3.2.1. Phage Display
4.3.2.2. Yeast Display
4.3.2.3. Ribosomal Display
4.3.3.    Transgenic Animal-Based Method
4.3.4.    Single B Cell-Based Method
4.3.5.    Advantages and Disadvantages of Existing Antibody Discovery Techniques
 
4.4.       Evolution of Monoclonal Antibodies
4.4.1.    Fully Human Monoclonal Antibodies
 
5.         ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
5.1.       Chapter Overview
5.2.       Antibody Discovery Service Providers: List of Industry Players
5.2.1.    Analysis by Year of Establishment
5.2.2.    Analysis by Company Size
5.2.3.    Analysis by Location of Headquarters
5.2.4.    Analysis by Type of Service Offered
5.2.5.    Analysis by Type of Antibody Discovery Method
5.2.6.    Grid Representation: Analysis by Type of Service Offered, Type of Antibody Discovery Method and Company Size
5.2.7.    Analysis by Animal Model Used
5.2.8.    Analysis by Type of Antibody Discovered
5.2.9.    Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
5.2.10.  Analysis by Purpose of Antibody Discovery
5.2.11.  Analysis by Type of Antibody Discovery Method and Purpose of Antibody Discovery
 
6.         COMPANY COMPETITIVENESS ANALYSIS
6.1.       Chapter Overview
6.2.       Methodology
6.3.       Key Parameters
6.4.       Competitiveness Analysis: Antibody Discovery Service Providers
6.4.1.    Antibody Discovery Service Providers based in North America
6.4.2.    Antibody Discovery Service Providers based in Europe
6.4.3.    Antibody Discovery Service Providers based in Asia Pacific
 
7.         COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
7.1.       Chapter Overview
7.2.       Antibody Discovery Service Providers in North America
7.2.1.    Abwiz Bio
7.2.1.1. Company Overview
Press Release: Variation 2 (Format 3)
 
7.2.1.2. Antibody Discovery Services
7.2.1.3. Recent Developments and Future Outlook
 
7.2.2.    Aragen Bioscience (A GVK BIO Company)
7.2.2.1. Company Overview
7.2.2.2. Antibody Discovery Services
7.2.2.3. Recent Developments and Future Outlook
 
7.2.3.    Distributed Bio
7.2.3.1. Company Overview
7.2.3.2. Antibody Discovery Services
7.2.3.3. Recent Developments and Future Outlook
 
7.2.4.    Integral Molecular
7.2.4.1. Company Overview
7.2.4.2. Antibody Discovery Services
7.2.4.3. Recent Developments and Future Outlook
 
7.2.5.    LakePharma
7.2.5.1. Company Overview
7.2.5.2. Antibody Discovery Services
7.2.5.3. Recent Developments and Future Outlook
 
7.3.       Antibody Discovery Service Providers in Europe
7.3.1.    Abzena
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Antibody Discovery Services
7.3.1.4. Recent Developments and Future Outlook
 
7.3.2.    ImmunoPrecise Antibodies
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Antibody Discovery Services
7.3.2.4. Recent Developments and Future Outlook
 
7.3.3.    PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
7.3.3.1. Company Overview
7.3.3.2. Antibody Discovery Services
7.3.3.3. Recent Developments and Future Outlook
 
7.4.       Antibody Discovery Service Providers in Asia-Pacific
7.4.1.    ChemPartner
7.4.1.1. Company Overview
7.4.1.2. Antibody Discovery Services
7.4.1.3. Recent Developments and Future Outlook
 
7.4.2.    Viva Biotech
7.4.2.1. Company Overview
7.4.2.2. Financial Information
7.4.2.3. Antibody Discovery Services
7.4.2.4. Recent Developments and Future Outlook
 
7.4.3.    WuXi Biologics
7.4.3.1. Company Overview
7.4.3.2. Financial Information
Press Release: Variation 2 (Format 3)
 
7.4.3.3. Antibody Discovery Services
7.4.3.4. Recent Developments and Future Outlook
 
8.         ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE
8.1.       Chapter Overview
8.2.       Antibody Discovery Platform Providers: List of Industry Players
8.2.1.    Analysis by Year of Establishment
8.2.2.    Analysis by Company Size 
8.2.3.    Analysis by Location of Headquarters
8.2.4.    Analysis by Type of Antibody Discovered
8.3.       Antibody Discovery: List of Technologies and Platforms
8.3.1.    Analysis by Type of Antibody Discovery Method
8.3.2.    Analysis by Type of Antibody Discovery Method and Location of Headquarters
8.3.3.    Analysis by Animal Model Used
8.3.4.    Analysis by Patent Availability
 
9.         TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1.       Chapter Overview
9.2.       Methodology
9.3.       Key Parameters
9.4.       Technology Competitiveness Analysis: Antibody Discovery Platforms
9.4.1.    Competitiveness Analysis: Library Based Antibody Discovery Platforms
9.4.2.    Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms
9.4.3.    Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
9.4.4.    Competitiveness Analysis: Other Antibody Discovery Platforms
 
10.        COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1.     Chapter Overview
10.2.     ImmunoPrecise Antibodies
10.2.1.  Company Overview
10.2.2.  Financial Information
10.2.3.  Portfolio of Antibody Discovery Platforms
10.2.3.1. Abthena™
10.2.3.2. B cell Select™
10.2.3.3. DeepDisplay™
10.2.3.4. ModiFuse™
10.2.3.5. ModiPhage™
10.2.3.6. ModiSelect™
10.2.3.7. ModiTune™
10.2.4.   Recent Developments and Future Outlook
 
10.3.     Harbour BioMed
10.3.1.  Company Overview
10.3.2.  Portfolio of Antibody Discovery Platforms
10.3.2.1. H2L2 Platform
10.3.2.2. HCAb Platform
10.3.3.   Recent Developments and Future Outlook 
 
10.4.     Kymab
10.4.1.  Company Overview
10.4.2.  Portfolio of Antibody Discovery Platforms
10.4.2.1. Kymouse™
10.4.2.2. IntelliSelect®
10.4.3.   Recent Developments and Future Outlook
 
10.5.     Ligand Pharmaceuticals
Press Release: Variation 2 (Format 3)
 
10.5.1.  Company Overview
10.5.2.  Financial Information
10.5.3.  Portfolio of Antibody Discovery Platforms
10.5.3.1. OmniAb®
10.5.3.1.1. OmniChicken®
10.5.3.1.2. OmniClic™
10.5.3.1.3. OmniFlic®
10.5.3.1.4. OmniMouse®
10.5.3.1.5. OmniRat®
10.5.4.  Recent Developments and Future Outlook
 
10.6.     MorphoSys
10.6.1.  Company Overview
10.6.2.  Financial Information
10.6.3.  Portfolio of Antibody Discovery Platforms
10.6.3.1. arYla® Technology
10.6.3.2. HuCAL® Technology
10.6.3.3. Ylanthia® Technology
10.6.4.  Recent Developments and Future Outlook
 
11.        REGIONAL CAPABILITY ANALYSIS
11.1.     Chapter Overview
11.2.     Key Assumptions and Methodology
11.3.     Regional Capability Analysis: Antibody Discovery Service Providers
11.3.1.  Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in North America
11.3.2.  Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Europe
11.3.3.  Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Asia-Pacific
 
11.4.     Regional Capability Analysis: Antibody Discovery Platform Providers
11.4.1.  Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in North America
11.4.2.  Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Europe
11.4.3.  Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Asia-Pacific
 
11.5.     Concluding Remarks
 
12.        PARTNERSHIPS AND COLLABORATIONS
12.1.     Chapter Overview
12.2.     Partnership Models
12.3.     List of Partnerships and Collaborations
12.3.1.  Analysis by Year of Partnership
12.3.2.  Analysis by Type of Partnership
12.3.3.  Analysis by the Type of Company (Service / Platform Providers)
12.3.4.  Analysis by Type of Antibody Discovered
12.3.5.  Analysis by Year of Partnership and Type of Partner
12.3.6.  Analysis by Type of Partnership and Type of Partner
12.3.7.  Most Active Players: Analysis by Number of Partnerships
12.3.8.  Most Popular Technologies: Analysis by Number of Partnerships
12.3.9.  Regional Analysis
12.3.9.1. Intercontinental and Intracontinental Agreements
 
Press Release: Variation 2 (Format 3)
 
13.        FUNDING AND INVESTMENT ANALYSIS
13.1.     Chapter Overview
13.2.     Types of Funding
13.3.     Antibody Discovery Service and Platform Providers: Funding and Investment Analysis
13.3.1.  Analysis by Number of Instances
13.3.2.  Analysis by Amount Invested
13.3.3.  Analysis by Type of Funding
13.3.4.  Most Active Players: Analysis by Amount Invested
13.3.5.  Most Active Investors: Analysis by Number of Funding Instances
13.3.6.  Regional Analysis by Amount Invested
 
13.4.     Concluding Remarks
 
14.        ANTIBODY DISCOVERY SERVICES: MARKET FORECAST
14.1.     Chapter Overview
14.2.     Forecast Methodology
14.3.     Global Antibody Discovery Services Market, 2020-2030 
14.4.     Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2020-2030
14.4.1.  Antibody Discovery Services Market for Antigen Designing, 2020-2030
14.4.2.  Antibody Discovery Services Market for Hit Generation, 2020-2030
14.4.3.  Antibody Discovery Services Market for Lead Selection, 2020-2030
14.4.4.  Antibody Discovery Services Market for Lead Optimization, 2020-2030
14.4.5.  Antibody Discovery Services Market for Lead Characterization, 2020-2030
14.5.     Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2020-2030
14.5.1.  Antibody Discovery Services Market for Phage Display, 2020-2030
14.5.2.  Antibody Discovery Services Market for Yeast Display, 2020-2030
14.5.3.  Antibody Discovery Services Market for Hybridoma Method, 2020-2030
14.5.4.  Antibody Discovery Services Market for Transgenic Animal Based Method, 2020-2030
14.5.5.  Antibody Discovery Services Market for Single Cell Based Method, 2020-2030
14.5.6.  Antibody Discovery Services Market for Other Methods, 2020-2030
14.6.     Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2020-2030
14.6.1.  Antibody Discovery Services Market for Humanized Antibodies, 2020-2030
14.6.2.  Antibody Discovery Services Market for Human Antibodies, 2020-2030
14.6.3.  Antibody Discovery Services Market for Chimeric Antibodies, 2020-2030
14.6.4.  Antibody Discovery Services Market for Murine Antibodies, 2020-2030
14.7.     Global Antibody Discovery Services Market: Distribution by Region, 2020-2030
14.7.1.  Antibody Discovery Services Market in North America, 2020-2030
14.7.2.  Antibody Discovery Services Market in Europe, 2020-2030 
14.7.3.  Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2020-2030
14.7.4.  Antibody Discovery Services: Market Attractiveness Analysis by Region
 
15.        ANTIBODY DISCOVERY TECHNOLOGIES: MARKET FORECAST
15.1.     Chapter Overview
15.2.     Key Assumptions
15.3.     Forecast Methodology
15.4.     Global Antibody Discovery Platforms Market, 2020-2030
15.5.     Global Antibody Discovery Platforms Market: Distribution by Region, 2020-2030
15.5.1.  Antibody Discovery Platforms Market in North America, 2020-2030
15.5.2.  Antibody Discovery Platforms Market in Europe, 2020-2030
15.5.3.  Antibody Discovery Platforms Market in Asia-Pacific, 2020-2030
 
16.        CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
16.1.     Chapter Overview
Press Release: Variation 2 (Format 3)
 
16.2.     Humira® (Adalimumab)
16.2.1.  Drug Overview
16.2.2.  Discovery Process and Method
16.2.3.  Historical Sales
 
16.3.     Keytruda® (Pembrolizumab)
16.3.1.  Drug Overview
16.3.2.  Discovery Process and Method
16.3.3.  Historical Sales
 
16.4.     Herceptin® (Trastuzumab)
16.4.1.  Drug Overview
16.4.2.  Discovery Process and Method
16.4.3.  Historical Sales
 
16.5.     Avastin® (Bevacizumab)
16.5.1.  Drug Overview
16.5.2.  Discovery Process and Method
16.5.3.  Historical Sales
 
16.6.     Rituxan® (Rituximab)
16.6.1.  Drug Overview
16.6.2.  Discovery Process and Method
16.6.3.  Historical Sales
 
17.        CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
17.1.     Importance of Antibody Humanization and Affinity Maturation
17.2.     Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
17.3.     Antibody Humanization: Publication Analysis
17.3.1.  Publication Analysis: Year-Wise Trend
17.3.2.  Publication Analysis: Key Journals
17.3.3.  Publication Analysis: Distribution by Animal Model Used
17.3.4.  Publication Analysis: Distribution by Method Used for Humanization
17.4.     Antibody Humanization Service and Platform Providers: SWOT Analysis
 
18.        FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
18.1.     Chapter Overview
18.2.     Anticipated Shift from Monoclonal Antibodies to Other Novel Formats
18.3.     Technological Advancements to Overhaul Conventional Antibody Discovery Processes
18.4.     Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
18.5.     Rising Demand for Antibody-based Treatment Options across Non-Oncology Indications
18.6.     Growing Market Opportunities in the Asia-Pacific Region
18.7.     Expected Increase in Number of Collaborations and Licensing Activity
18.8.     Concluding Remarks
 
19.        EXECUTIVE INSIGHTS
19.1.     Chapter Overview
 
19.2.     Abveris Antibody
19.2.1.  Company Snapshot
19.2.2.  Tracey Mullen, Chief Executive Officer (Q2 2020)
 
19.3.     Nidus Biosciences
19.3.1.  Company Snapshot
19.3.2.  Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)
Press Release: Variation 2 (Format 3)
 
19.4.     AvantGen
19.4.1.  Company Snapshot
19.4.2.  Mark Kubik, Chief Business Officer (Q1 2020)
 
19.5.     Single Cell Technology
19.5.1.  Company Snapshot
19.5.2.  Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)
 
19.6.     Distributed Bio
19.6.1.  Company Snapshot
19.6.2.  Giles Day, Co-Founder and Chief Executive Officer (Q2 2018)
 
19.7.     AbCellera
19.7.1.  Company Snapshot
19.7.2.  Kevin Heyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)
 
19.8.     AbGenics Life Sciences
19.8.1.  Company Snapshot
19.8.2.  Sanjiban K Banerjee, Director (Q2 2018)
 
19.9.     CDI Laboratories
19.9.1.  Company Snapshot
19.9.2.  Ignacio Pino, Chief Executive Officer and President (Q2 2017)
 
19.10.   AP Biosciences
19.10.1. Company Snapshot
19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)
 
19.11.   YUMAB
19.11.1. Company Snapshot
19.11.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)
 
19.12.   Antibody Solutions
19.12.1. Company Snapshot
19.12.2. Debra Valsamis, Business Development Associate (Q2 2017)
 
19.13.   Ligand Pharmaceuticals
19.13.1. Company Snapshot
19.13.2. Christel Iffland, Vice President (Q2 2017)
 
19.14.   LakePharma
19.14.1. Company Snapshot
19.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)
 
20.        CONCLUDING REMARKS
20.1.     Chapter Overview
20.2.     Key Takeaways
 
21.        APPENDIX 1: TABULATED DATA
 
22.        APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
1329 Posts

Made with by Mamby